ULURU INC.
ULU evidence brief
What we can confirm
- BioSniper Score:
- 6.7 / 10
- Lead Asset:
- altrazeal (Approved)
What it means
What to watch
Prepared research question
What matters most for ULU—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
altrazeal (Approved)
Next Catalyst
—
Tracking 1 pipeline candidate · 3 clinical trials for ULURU INC..
Run ULURU INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ULURU INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Approved
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Governance
Frequently asked questions
What is ULURU INC.'s lead drug candidate?
ULURU INC.'s most advanced tracked candidate is altrazeal (Approved) for exuding acute wounds such as partial thickness burns, donor sites, non-healing surgical wounds, and trauma and for chronic wounds such as venous leg ulcers, diabetic foot ulcers, and pressure ulcers.
Who is the CEO of ULURU INC.?
Beltway Drive Addison is the chief executive officer of ULURU INC. (ULU).
What therapeutic areas does ULURU INC. focus on?
ULURU INC. develops therapies across Oncology, Pain.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.